|
|
|
| Correlation analysis of disease severity and anti-thyroid antibody level in patients with Guillain-Barré syndrome |
| LIU Zhiwei LI Yimeng ZHANG Haifeng LIAN Yajun CHENG Xuan |
Department of Neurology, the First Affiliated Hospital of Zhengzhou University, Henan Province, Zhengzhou 450052, China
|
|
|
|
Abstract Objective To analyze the correlation of disease severity with antithyroid antibody and thyroid hormone in patients with Guillain-Barré syndrome (GBS). Methods A total of 163 GBS patients admitted to the First Affiliated Hospital of Zhengzhou University from October 2013 to March 2021 were selected. They were classified as mild group (50 cases) and severe group (113 cases) according to the Hughes functional grading scale score. Clinical data of patients were collected, and the correlation between disease severity and antithyroid antibody and thyroid hormone, and the risk factors influencing disease severity were analyzed. Results The course of disease before admission in severe group was shorter than that in mild group, and age, the levels of anti-thyroid peroxidase autoantibody (aTPOAb), and anti-thyroid globulin antibody (aTGAb) were higher than those in mild group, and the differences were statistically significant (P < 0.05). The disease severity of GBS patients was positively correlated with serum aTPOAb and aTGAb levels (r =0.366, 0.394, P < 0.05), but not with thyroid-stimulating hormone level (P > 0.05). Age and aTGAb level were the influencing factors of disease severity (OR > 1, P < 0.05). Conclusion ATGAb is an independent risk factor for disease severity in GBS patients. The older the age, the higher the level of aTGAb, and the more severe the disease of GBS patients.
|
|
|
|
|
|
[1] Shahrizaila N，Lehmann HC，Kuwabara S. Guillain-Barre syndrome [J]. Lancet，2021，397（10280）：1214-1228.
[2] van Koningsveld R，Steyerberg EW，Hughes RA，et al. A clinical prognostic scoring system for Guillain-Barre syndrome [J]. Lancet Neurol，2007，6（7）：589-594.
[3] Leonhard SE，Mandarakas MR，Gondim FAA，et al. Diagnosis and management of Guillain-Barre syndrome in ten steps [J]. Nat Rev Neurol，2019，15（11）：671-683.
[4] Willison HJ，Jacobs BC，van Doorn PA. Guillain-Barre syndrome [J]. Lancet，2016，388（10045）：717-727.
[5] van den Berg B，Walgaard C，Drenthen J，et al. Guillain-Barre syndrome：pathogenesis，diagnosis，treatment and prognosis [J]. Nat Rev Neurol，2014，10（8）：469-482.
[6] Principi N，Esposito S. Vaccine-preventable diseases，vaccines and Guillain-Barre’ syndrome [J]. Vaccine，2019， 37（37）：5544-5550.
[7] Papri N，Islam Z，Leonhard SE，et al. Guillain-Barre syndrome in low-income and middle-income countries：challenges and prospects [J]. Nat Rev Neurol，2021，17（5）：285-296.
[8] Walgaard C，Jacobs BC，Lingsma HF，et al. Second intravenous immunoglobulin dose in patients with Guillain-Barre syndrome with poor prognosis（SID-GBS）：a double-blind，randomised，placebo-controlled trial [J]. Lancet Neurol，2021，20（4）：275-283.
[9] Doets AY，Verboon C，van den Berg B，et al. Regional variation of Guillain-Barre syndrome [J]. Brain，2018，141（10）：2866-2877.
[10] Walgaard C，Jacobs BC，Lingsma HF，et al. Second IVIg course in Guillain-Barre syndrome patients with poor prognosis（SID-GBS trial）：Protocol for a double-blind randomized，placebo-controlled clinical trial [J]. J Peripher Nerv Syst，2018，23（4）：210-215.
[11] Wang X，Yi H，Liu J，et al. Anti-thyroid antibodies and thyroid function in neuromyelitis optica spectrum disorders [J]. J Neurol Sci，2016，366：3-7.
[12] Huang Y，Ying Z，Chen Z，et al. Thyroid hormone level is associated with the frequency and severity of Guillain-Barre syndrome [J]. Int J Neurosci，2017，127（10）：893-899.
[13] Long Y，Zheng Y，Chen M，et al. Serum thyroid-stimulating hormone and anti-thyroglobulin antibody are independently associated with lesions in spinal cord in central nervous system demyelinating diseases [J]. PLoS One，2014，9（8）：e100672.
[14] Li H，Dai Y，Wu AM，et al. Anti-thyroid antibodies and cerebrospinal fluid findings in neuromyelitis optica spectrum disorders [J]. J Neuroimmunol，2015，281：38-43.
[15] He Q，Li L，Li Y，et al. Free thyroxine level is associated with both relapse rate and poor neurofunction in first-attack Neuromyelitis Optica Spectrum Disorder（NMOSD）patients [J]. BMC Neurol，2019，19（1）：329.
[16] Asbury AK，Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barre syndrome [J]. Ann Neurol，1990，27 Suppl：S21-S24.
[17] Hughes RA，Newsom-Davis JM，Perkin GD，et al. Controlled trial prednisolone in acute polyneuropathy [J]. Lancet，1978，2（8093）：750-753.
[18] Tu Y，Gong X，Zeng G，et al. Differences in Thyroid Function and Autoantibodies in the Development of Guillain-Barre Syndrome vs. Chronic Inflammatory Demyelinating Polyradiculoneuropathy [J]. Front Neurol，2020，11：1018.
[19] Sakuma R，Fujihara K，Sato N，et al. Optic-spinal form of multiple sclerosis and anti-thyroid autoantibodies [J]. J Neurol，1999，246（6）：449-453.
[20] Dawe K，Hutchings P，Champion B，et al. Autoantigens in thyroid diseases [J]. Springer Semin Immunopathol，1993，14（3）：285-307.
[21] Liu S，Xiao Z，Lou M，et al. Guillain-Barre syndrome in southern China：retrospective analysis of hospitalised patients from 14 provinces in the area south of the Huaihe River [J]. J Neurol Neurosurg Psychiatry，2018，89（6）：618-626.
[22] Song Y，Zhang Y，Yuki N，et al. Guillain-Barre syndrome in Eastern China：A study of 595 patients [J]. Eur J Neurol，2021，28（8）：2727-2735.
[23] Peric S，Bozovic I，Bjelica B，et al. Diabetes mellitus may affect short-term outcome of Guillain-Barre syndrome [J]. J Peripher Nerv Syst，2017，22（2）：127-130.
[24] Briseno-Godinez ME，Arauz A，Lopez-Hernandez JC，et al. Prognostic Factors in Elderly Patients With Guillain-Barre Syndrome：Does Age Matter? [J]. Neurohospitalist，2021，11（4）：303-309.
[25] Wen P，Wang L，Liu H，et al. Risk factors for the severity of Guillain-Barre syndrome and predictors of short-term prognosis of severe Guillain-Barre syndrome [J]. Sci Rep，2021，11（1）：11578.
[26] Montalvo R，Castaneda A，Lopez JA，et al. Disease progression velocity as predictor of severity in Guillain-Barre syndrome [J]. Rev Peru Med Exp Salud Publica，2021，38（1）：17-23. |
|
|
|
